# Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

> **NCT02229253** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 112 (actual)

## Conditions studied

- Advanced Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** degarelix

## Key facts

- **NCT ID:** NCT02229253
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-10-04
- **Final completion:** 2017-10-04
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229253, "Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02229253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*